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Perspectives on Testing for Toxic Agents
by Norton Nelson*-
A series of observations and comments are made with respect to several areas of toxicology: these are
briefly discussed. Some innovative areas receive discussion as representing substantial progress made in
the field of toxicology in recent years. Topics included raise a number of questions: what agents should
we test, and how should we go about selecting them; what is the importance of allowing for genetic
diversity in carrying out tests that are meaningful for humans; and what is the relevance of studies in
pharmacokinetics in the laboratory to humans. Human studies, because of ethical considerations, must
be indirect, through access to available autopsy and surgical human tissues. Also, drug trials and clinical
studies must be exploited.
Cancer testing and evaluation is briefly commented on. Systemic toxicity is considered in respect to
possible improved ways ofdetermining the "NOEL," that is, the no-observed-effect level. Suggestions for
improving study of mixtures of chemicals are considered. The rapid advances in molecular biology have
significantly strengthened ourabilitytotracethe action ofchemicals inthe bodyfromexposuretodisease.
It is very important that training in toxicology be based on a sound disciplinary training in one of the
classic fields ofthe biomedical sciences, such as biochemistry, pharmacology, molecular biology.
It is concluded that advances in the past decade have made the practice of toxicology a much more
scientific endeavor, especially in its use ofthe latest developments in basic biomedical sciences.
Introduction
I would like to use the broad license given me by the
title to make a series ofcomments on a field that I have
participated in and observed for a number of years.
These observations lead me to the conclusion that al-
though much solid and impressive progress has been
made over the years, a few other areas have, in a rel-
ative sense, lagged.
My view ofthe boundaries of toxicology may not be
accepted by all. I include informationgathered fromthe
study of human experience (epidemiology) and the use
of surgically available human tissues within my defini-
tion, always, of course, with full regard for ethical con-
siderations, which exclude human experiments.
What Should We Test?
What chemicals should we test? As illustrated in Fig-
ure 1 (1), thestudycarriedoutbythe NationalAcademy
of Sciences under the sponsorship of the National In-
stitute of Environmental Health Sciences (NIEHS) il-
lustrates the very large number of untested or inade-
quately tested chemicals. The same study proposed a
method for establishing priorities for the testing of
chemicals. This may or may not be the best technique;
there are others. One technique developed under the
National Science Foundation a few years back had to
do with a priority assessment technique that depended
on the total amount of material produced, modified by
*NewYork University Medical Center, Institute ofEnvironmental
Medicine, New York, NY 10016.
what was called its "release rate" (2). The release rate
is the fraction of the material that goes back immedi-
ately into a new synthetic process. Obviously, it is the
releaserate ofa chemicalthatdeterminesmore directly
than total production whether or not the chemical is
likely to become widespread in the community; of
course, the extent of handling within a plant can, in
some degree, alter occupational exposure.
The current premarket notification system which our
present Toxic Substances Act requires is very general;
thus, the very minimum amount of information is re-
quired before a chemicalis permitted to enterinto man-
ufacturinganduse. Currentlythesystemisverylargely
based on little more than structure-activity relation-
ships. It is true that EPA can, on the basis of their
study, request additionaltestingunderthe presentlaw.
It may well be that Congress should reexamine the
Toxic Substances Act and see whether more stringent
requirements for premarket testing should not be re-
quired as, in fact, is the case in some other countries.
Obviously, the testing responsibilities would be differ-
ent depending on whether the responsibility should be
that ofmanufacturer orwhetherthe chemical is already
in the common domain for which no one manufacturer
has specific responsibilities. There should clearly be
more information available before manufacturing pro-
ceeds.
Genetic Diversity
There is an element of partial self-delusion involved
in the choice of inbred strains in toxicity tests. InbredN. NELSON
Size of Estimated Mean Percent
Category Category in the Select Universe
Pesticides and Inert
Ingredients of Pesticide
Formulations
Cosmetic Ingredients
Drugs and Excipients
Used in Drug Formulations
Food Additives
Chemicals in Commerce:
At Least 1 Million
Pounds/Year
Chemicals in Commerce:
Les than 1 Million
Pounds/Year
Chemicals in Commerce:
Production Unknown or
Inaccessible
3,350
3,410
1,815
8,627
12,860
13,911
21,752
10 24 2 26 38
2 1410 18 56
. -.-...............
18 18 3 36 25
. ... ........
2 14 1 85
....
5 14 1 34 46
11 11 78
12 12 76
10 8 82
Complete Partial Minimal Some
Health Health Toxicity Toxicity
Hazard Hazard Information Information
Assessment Assessment Available Available
Possible Possible (But below Minimal)
FIGURE 1. Ability to conduct health-hard assessment of substances in seven categories of select universe.
strains, of course, lead to more orderly and repeatable
tests, which increase the likelihood ofgetting more com-
parability in tests carried out in different laboratories
and at different times. This is, of course, a desirable
objective, but we should also keep in mind that another
objective in toxicological appraisals is to use the strain
or strains that best mimic the human responses or, fail-
ing that, the most sensitive strain. The approach based
on using the strain or species that is either most sen-
sitive ormostfaithfully mimicshumanresponseisrarely
supported by any actual evidence to support such
choices.
One possible approach to this objective might be the
addition of at least one genetically diverse species or
strain alongside the highly studied inbred strains. Ob-
viously, pharmacokinetic data supporting parallels be-
tween humans and test animals can be very helpful in
choosing the test strain.
We are well aware ofthe wide range insusceptibilities
in humans and at least give lip service to the need for
protection of the susceptible components of the popu-
lation. Nevertheless, we live to a substantial degree in
ignorance of the range of susceptibilities. One can, for
example, look at the work of Harris (3), which dealt
with the capabilities of human tissues to bind aromatic
hydrocarbons as at least one measure ofthe very wide
diversity in biochemical interaction in humans (Fig. 2).
With the current major advances in genetic character-
ization, this field is capable of advancing very rapidly.
Another example is from the work by the Palmes
group (Fig. 3) (4) on the wide diversity in the dimen-
sional aspects of human pulmonary structure. This di-
versity influences susceptibility because particle depo-
sition will be altered by the differences in small airway
dimensions in the pulmonary system; variations in the
extent and pattern of deposition will alter response to
inhaled toxic particles.
Aslaboratorytestsfortoxicityexpandandproliferate
and become more routinized, one sees fewer and fewer
studies on larger animals such as dogs, cats, and pri-
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FIGURE 2. The interindividual variation in the binding levels ofBP
to DNA in cultured human bronchi. The values marked with an
asterisk are from patients without lung cancer and the remainder
are from lung cancer patients.
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FIGURE 3. Distribution ofairspace diametersbyaerosolpersistence
compared with diameters ofsmall (< 2mm) nonalveolated airways
found by Matsuba and Thurlbeck (20). The ordinate refers to the
percent of airspaces less than the stated diameter.
mates; these have never been studied in large numbers
but, nevertheless, have been sometimes extremely use-
ful in disclosing patterns of response that rodents do
not show. Thus, the specificity ofthe dog in responding
to bladder cancer with aromatic amines (mimicking hu-
man responses) would have been missed had we been
dependent on the current procedures using rodents
only.
Pharmacokinetics
For many years toxicologists have urged the impor-
tance ofthe understanding ofthe comparative behavior
of chemicals in the test species and man for valid pre-
diction of effects in man. This requires a pharnacoki-
neticmodel ofexposure and selective entryinto various
parts of the body where it is metabolized or excreted,
or both. This is shown in Figure 4 where we illustrate
a somewhat simplified mammal capable of taking up
external chemicals through the lungs, throughthe skin,
and through the mouth; subsequently, the agent or its
products move through the organism subject to a va-
riety of processes ofdiffusion, circulation, metabolic al-
teration, and eventually excretion. This scenario rep-
resents those classical processes which we collectively
call the pharmacokinetic handling of chemical agents,
which we have grappled with for many years; but we
are now becoming more and more aware of the vital
importance of such considerations in the study of the
effectsofforeignchemicals onthemammalianorganism.
Both species diversity and genetic diversity within
species force us to use a variety of approaches to at-
tempt to secure valid predictions for humans through
the study ofboth human and nonhuman organisms.
Human Studies
As noted earlier, the realm of toxicology should not
stop with laboratory studies. There are many sources
ofinformation fromhuman populations that canbeused
to strengthen our attempts to protect humans from
d-resp.
Respiration
Lungy,
Heart-|
d -oral
in
FIGURE 4. A mammal (slightly simplified).
c
cr
'I
E
99
_N. NELSON
chemical threats (6). These sources include fuller use of
drugtrials, fulleruseofavailable humantissuesasprac-
ticed by Harris (3), and fuller use ofthose examples in
clinical medicine that can inform on human responses.
Amajoradvance overtheyearshasbeentheemergence
of ethical considerations that have prevented reckless
and needless experimentation on humans. There are,
nevertheless, while avoidingthis, datathat canbe very
instructive ifwe exploit the information being collected
in our hospitals and clinics. It is in this sense that
NIEHSplanstodevelop aseries ofclinical andresearch
training appointments in which toxicological interests
are linked to clinical units for the fuller exploitation of
human experiences to help provide information on hu-
man responses.
Comments on Cancer Testing and
Evaluation
Our understanding of the mechanisms of cancer in-
duction have improved dramatically over the last 15
years; many profoundly important advances have been
made. With the emergence of the oncogene, we have
some more exciting years ahead. On the other hand,
theancient PHS Publication 149 (7) hasbeen since 1948,
and still is, a highly useful and fruitful source ofinfor-
mation.
Although the use of quantitative risk assessment
(QRS) is now more or less routine in the evaluation of
carcinogens, it may be too comfortably accepted by
many people. Those who practice it, as well as those
who have observed its use, need a healthy skepticism
as to the validity and reliability of these procedures.
Nevertheless, QRS is anindispensable step in the eval-
uation of carcinogenic potency. Moreover, the use of
QRS has led to a more critical evaluation of the basic
data in relating to carcinogenesis and has the potential
ofimproving protocol design and test procedures.
The Ames (8) procedure has been an extraordinarily
powerful tool for assessing mutagenicity and carcino-
genicity; itpromises still broaderreliability with newer
supplementary procedures (9) in expediting the very
heavy burden oftesting chemicals for carcinogenicity.
There is sometimes a tendency in our study of the
biological effects ofxenobiotics to assume that by nam-
ing the process or the response, we have solved the
biologicalcomplexities involved. Aprimeexampleisthe
use ofthe term "promotion" in the multistage carcino-
genesismodel. Theassumptionappearstobesometimes
made that all promoting mechanisms are biologically
similar. Is the response to phorbol ester on the skin of
mice after a single application of benzopyrene a truly
comparable mechanism to that present in the use of
barbituates following initiation in the study of rodent
liver cancer? Premature classification based on opera-
tionalsimilarities cansometimesdiscourage seekingun-
derlying biological differences.
Asomewhat similarpositionisperhaps evidentinthe
field of metal carcinogenesis. An understanding of the
processesbywhichmetalcompoundsinducemalignancy
has been hindered sometimes by the assumption that
metalspersehavesimilarbiologicalmechanismsintheir
carcinogenic action. In fact, there may be as much dif-
ference among the various species ofmetal compounds
as there is from one group of metals to another. Ac-
cordingly, oneshouldnotseekforeasyclassificationthat
may obscure the real differences lying behind the bio-
logical processes.
Systemic Toxicity
Theevaluation ofnoncarcinogenicresponseshavenot
been conceptually changed in any major way over the
years. We still depend largely on tests in laboratory
animals for the detection ofa range ofdose responses,
including the estimation of a no-effect level. As noted
below, short-term tests still play only a modest role in
evaluating systemic toxicity.
The "O" in the NOEL (10) recognizes that the no-
observed-effect level states the reality as to what was
orwas not seen. However, atits crudest, thisis an area
innoman'sland, inwhichtheNOEL ishighlyinfluenced
(even wholly dependent) on the size of the group and
the interval in spacing ofthe doses. It makes use ofno
morethantwopointsinwhatmightotherwisebeawell-
conducted multidose study. More recently, and else-
where (5), I have suggestedadifferentapproachtoward
the estimation of what might be called a "computed
NOEL." A computed NOEL would be based on the
fitting ofthe dose-response data to any one ofthe clas-
sicalmodels (logit, probit) overtherangeoftestdosage.
Thatistosay, the NOEL iscalculated, fromtheearliest
detected effect allthewayuptothehighestdose, which
stillshowstheearliesteffectdetected. Forthispurpose,
it matters relatively little which dose-response curve is
used, overthe normal group size; it will not make much
difference which curve is chosen. One now computes
the lowest frequency of occurrence that is likely to be
observed (or missed) with the particular group size
used. If one then takes the dose from the fitted curve
at that point, one has chosen a point on the curve that
is at the borderline of observing or not observing an
effect. This can thus be regarded as a computed, or a
synthetic, NOEL. Such a NOEL has the immense ad-
vantage that one can use allthe pointsthat are relevant
and available and can do so within the context oftheir
statistical validity so that confidence limits can be cal-
culated.
What one then does with this computed or synthetic
NOEL is a separate issue, not really very much differ-
ent than what one would do with a so-called observed
NOEL. Alogicalapproachistodeterminethecomputed
NOEL and draw a line down to zero or the normal
background occurrence. One may then, in a risk man-
agement sense, choose the appropriate risk point; in-
deed, the slope of that extrapolated line may serve as
an index of potency. Conversely, one may choose to
divideitbyanyoneofthecommonlyusedsafetyfactors,
10, 100, or 1000, depending on the risk management
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circumstances imposed by nontoxicological considera-
tions.
Attempts to develop short-term tests for other sys-
tems and organs along the lines of the Ames test (8)
have been much less promising and are certain to be
more difficult, since, at least in part, the underlying
biological processes are not as well understood (a state-
ment perhaps many would challenge). A recent study
that systematically sought improved short-term test
procedures inisolated systemsforendpoints otherthan
genotoxicity has produced many useful approaches to
the problem but did not, in fact, succeed in identifying
majorsimplifiedtestsoftheeffect ofchemicals onentire
organs or organ systems (11). This review was only a
beginning and needs substantially more work; such
studies should be given strong encouragement and sup-
port.
Mixtures
Toxicologists live uncomfortably with the assumption
that humans are exposed to pure chemicals when they
know that, almost invariably, mixtures are involved.
Often the mixtures are very complex. The evaluation
oftoxicity based on information from pure chemicals is
often predictive of the toxicity of mixtures. Repeated
endeavors have been made to develop what may be
called a "calculus" for deducing the effect of mixtures
from data on single chemicals. This has largely failed
except where the chemicals have similar effects; this
was very well examined many years ago (12). A recent
systematic and extended study (SGOMSEC 3) (13) has
a number ofuseful proposals for study ofmixtures.
This may be an area in which an orderly application
ofsome ofthenewercomputertechniques fordissection
ofcomplexmoleculeswithattributionofdifferentmodes
of action to separate components could usefully be ex-
ploredtocharacterizemixturesofchemicals. Thiswould
suggest the consideration of a deliberate set of studies
in which mathematical and computer approaches (14-
16) could be applied to the analysis of biological tests
of carefully selected mixtures as an approach to the
development of practical techniques for studying the
biological responses to mixtures ofunrelatedchemicals.
Short Cuts
We are confronted with an extraordinary amount of
needed information on chemicals not previously tested
or inadequately tested in the past. This will require
much more work, but also a great deal ofingenuity in
findingmore efficient and informative ways to dealwith
what would otherwise be an overwhelming task. We
thus seek short cuts.
There are currently intoxicology some simplifications
which, althoughperhapsuseful, do notinstillimmediate
confidence that they produce accurate results. One is
the relationship between toxicity and carcinogenicity
(17). That there should be a correlation is not really
very surprising; however, it would be very surprising
if, infact, therewerenotmanyexceptionstothepartial
parallelismthathasbeenobserved. Itcouldwellbethat
study ofthe exceptions may be more useful than study
ofthe parallelism; the basis for the differences may be
very instructive.
In the face ofthe enormous mass ofnew information
required, there is search for simplifying assumptions
bothinthe conduct oftests and intheirevaluation. This
has led, in some instances, to the search for much sim-
plified, even single, indices of toxicity. This is an en-
deavor which has some utility in setting priorities for
limited purposes but has intrinsically many dangers in
the likelihood ofobscuring the very important features
which can only be expressed in terms of a narrative
statementwhichincludestheappropriate qualifications.
We should be very wary of inappropriate use of over-
simplification, despite the fact that they may havejus-
tifiable applications in limited areas.
A very promising example ofwhat should not be re-
garded as a short cut, but as a broad spectrum of ac-
celerated toxicity tests that deserves careful study as
producing a well-rounded body of information, is con-
tained inthe NTP studyonmethylisocyanate (18). This
exercise welded together proven toxicological tech-
niques ofthe past with very recent advances in devel-
oping information on a wide range of important end
points. This entire study was completed in some 8
months and yielded a remarkably broad and rich body
of information which will certainly provide, as a mini-
mum, a basis for more detailed studies and in some
cases, willeliminatetheneedformoreextendedstudies.
It can set an example ofefficient choice and application
of our advancing skills in toxicology.
Thus, the full exploitation ofthe advances in toxicol-
ogy ofthe last few years, building on the still relevant
remnants ofthe past, can provide much improved ways
ofdealingwiththe awesomebodyofneededbutmissing
information.
Markers
The word "marker" has come into fashion to replace
the word "indicators." These indicators ormarkers are,
indeed, a very interesting mixture of older topics for
whichwe now have somewhatdifferentnames andvery
much newer knowledge which emerges directly out of
the very forefront of the science that has been devel-
oping in the last few years, molecular biology.
Figure 5 (19) represents such a blending of the old
and the new. Thisblendingis, infact, afillinginofgaps
of ignorance that confronted us just a few years ago.
Whereas, at one time, we spoke of exposure and the
effect without dwelling in any great detail on the bio-
logical events lying between exposure and effect, we
now can speak often with very great circumstantiality
and detailaboutthe eventsoccurringbetweenexposure
and the effect or disease itself.
Figure5originatedunderacontractbetweenNIEHS
and EPA with the Council on Environmental Quality
and the National Science Foundation (19). It is now
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FIGURE 5. Markers ofexposure and effects.
possible to identify a series of steps lying between ex-
posure andthepenultimate orultimate effect. Theterm
markers (orindicators) has been widely adopted now to
cover the whole series ofstages or transitions between
external exposure and ultimate effect, which may be
disease or death; one can now identify some ofthe spe-
cific biochemical events that are associated with these
progressive markers.
Thetermmarkerasusedhererepresents asequential
orparallel step or transition in the movement ofevents
fromearly exposure to overtbiochemical disorder, onto
an easily visible effect, and, in some cases, outright
disease. The chart is deliberately rather fuzzy with re-
spect to the number of marker transitions or marker
events because there are still many blanks to be filled
and because they can serve to cover many different
phenomena. Figure 5 starts with external exposure,
progresses through absorption and movement to an in-
ternal dose, hence, to a biologically effective dose or
molecular dose (where they may be called biological
markers or exposure indicators), onto a preclinical re-
sponse from which stage they pass on to clinical effects
and disease. In some cases, one might consider surro-
gate biological markers in addition or instead of the
actual biological markers. The uptake ofethylene oxide
or other alkylating agents through interaction with
hemoglobin could be such a surrogate marker; that is,
an agent that might be deliberately administered in or-
der to trace the extent to which it does interact with
biochemical molecules. Or, one may look at a cell which
is accessible, e.g., a leukocyte as a surrogate cell for
one less accessible.
Looking at the bottom of the Figure 5, one can see
that there are numerical exponents which are intended
to crudely indicate the level ofdetectability orthe level
of involvement of the phenomenon at several stages.
The stages may start, for example, with the part per
billion detectability for the exposure dose, progress
through a detection of the molecular dose at the level
of one in 10 million, to a biological marker at a level of
oneinamillion, finallytodiseasewherethemarkermay
be detectable only at the order of 1%. There are ob-
viouslyaseries ofstepsinbetweenmanyofthesemark-
ers which, atthis stage, may defy detection oranalysis.
Theifilinginofwhat were untilrecently blank spaces
inachartsuchasthisisinitselfamajoraccomplishment
in science. In many instances, a marker can identify
specific entities, e.g., an adduct on a protein or an ad-
duct on DNA, which not only marks evidence ofinter-
action, but may in itselfbe a marker ofan altered bio-
chemicalunit which can have grave consequences, e.g.,
through a mutated DNA which can lead eventually to
cancerinduction inthe tissues involved. Suchincreased
sensitivity and specificity gives promise of being able
to detect at a much earlier stage the progression of
eventsthatmayhavegraveconsequencesforthebearer
of particular markers. As such, the promise of earlier
detection ofthe action oftoxicants can have important
public health benefits.
Obviously, all such markers do not carry with them
such grave consequences; some may be simply transi-
tional interactions with a protein or biochemical unit
which when that particular protein or biochemical unit
isreplaced will disappearforever. Butconceptually, we
can now begin to look more closely at the intervening
events between exposure to a foreign chemical, the na-
ture of its action, and the likelihood of the outcome of
the biological interaction.
Training
The field of toxicology is perhaps not as new as is
sometimes supposed. In the 1940s, training programs
were rare and essentially nonexistent in the sense of
being specifically designed to train toxicologists. The
recruitment into the field came from a few disciplines,
heavily pharnacology and biochemistry, with smaller
numbers from other allied fields, includingchemistryin
all its branches. I direct my attention to a career in
which the objective is to improve our understanding of
the mechanisms ofaction oftoxicants either in general
biological terms or specifically aimed at a contribution
to the eventual incorporation of such infornation into
the test arnamentarium, and to improve efficiency and
sensitivity ofthe detection ofinjury.
Nothing can substitute for a solid basic disciplinary
trainingin one ofthe classic fields ofscience, beitphar-
macology, biochemistry, cell biology, or, even better, a
selection ofthese fields with a clear focus on the appli-
cationtotoxicology. Thismaybelongerandmoredrawn
out than normal training restricted to a classic field of
science, but I believe ittobe the besttrainingforthose
whoaresearchingtounderstandhowchemicalsproduce
injury.
Awell-rounded predoctoraland postdoctoraltraining
within the classic disciplines teaches one not only the
basic techniques (transient though they be) in the bio-
logical sciences but, most importantly, teaches a very
important lesson, that is, how to recognize the uncer-
tainties encountered inbiological research and the need
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to be constantly ready to alter one's approach, to alter
one's thinking, and to instill the requisite skepticism in
looking at a body of data to test it for its soundness,
coherence, and relevance.
Itshould furtherbesaidthatthisimpliesasubstantial
period oftime inthe direct conduct ofresearch. Indeed,
I would feel that the specifics of that research are rel-
atively unimportant. It is, however, very important to
work closely with a mentor of critical mind and imagi-
nation who is willing to give the neophyte a loose rein
fortrialanderrorinthelearningexperience. Oneshould
not, in this arena, be too much concerned by the name
that is applied to the course of study. Some programs
called toxicology are, unfortunately, routinely oriented
to the simplest kind of repetitive testing. Others, in
fact, have at their base the ingredients of an excellent
basic discipline in one or several of the biological sci-
ences. Obviously, whatever be the major route, total
restriction to the biological sciences is, ofcourse, short-
sighted in these days when competence in the physical
techniques and computer resources with grounding in
the physical and mathematical sciences is essential.
One can accept that training for the more basic prac-
tice oftoxicology can be done within any qualified basic
department ofbiological science. However, there is an
important bonus when such basictrainingoccurs within
a program committed to the basic field of toxicology;
this brings directly and at an optimal period an orien-
tation in the breadth and linkages ofthe field.
In summary, toxicology as a field has matured and
grown into a science that can now, and does, command
the commitment ofthe best scientists in the biomedical
arena. Indeed, it is returning new and fruitful ideas to
the basic sciences from which its own inspirations and
advances-were drawn.
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